Target intelligence / Profile preview

Hepatitis E virus non-structural polyprotein (ORF1) (HEV ORF1)

Target
HEV ORF1
Molecular classification
Enzyme, RNA-dependent RNA polymerase, Helicase, Methyltransferase, Protease
01

Overview

The Hepatitis E virus (HEV) replication machinery is primarily composed of the non-structural polyprotein encoded by Open Reading Frame 1 (ORF1) (UniProt: P0C1Z1). This polyprotein is a multi-domain enzyme complex essential for viral genome replication and transcription, containing methyltransferase (MeT), papain-like cysteine protease (PCP), helicase (Hel), and RNA-dependent RNA polymerase (RdRp) domains (PubMed: 32824397). These domains coordinate the capping of viral RNA, the unwinding of double-stranded RNA intermediates, and the synthesis of new positive-sense RNA genomes (NCBI: NBK537279). As the central engine of the HEV life cycle, the ORF1 polyprotein is the primary target for therapeutic intervention, particularly in chronic cases affecting immunocompromised individuals (PubMed: 30103439). While current treatments like ribavirin and interferon-alpha are used, they are not specific to HEV and are associated with significant side effects and resistance mutations, such as the G1634R substitution in the RdRp domain (PubMed: 27535008). Consequently, the development of direct-acting antivirals (DAAs) targeting the specific enzymatic activities of the HEV replication machinery remains a critical area of clinical research.

Other names
ORF1 polyproteinHEV replicaseHEV non-structural proteinHepatitis E virus replication complex
02

Mechanism of action

Inhibition of RNA-dependent RNA polymerase (RdRp) activity, induction of lethal mutagenesis, and inhibition of viral RNA capping and helicase functions.

03

Biological functions

Viral replicationRNA synthesisViral cappingPolyprotein processingRNA helicase activity
04

Disease associations

Hepatitis EInfectionLiver cirrhosisAcute liver failure
05

Safety considerations

Ribavirin-induced anemiaTeratogenicityDevelopment of antiviral resistance (e.g., G1634R mutation)Limited efficacy in certain genotypes
06

Interacting drugs

Ribavirin

3 more in the full profile.

07

Biomarkers

HEV RNAAlanine aminotransferase (ALT)Aspartate aminotransferase (AST)HEV antigen (HEV Ag)

Beyond the preview

Go deeper on Hepatitis E virus non-structural polyprotein (ORF1) (HEV ORF1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hepatitis E virus non-structural polyprotein (ORF1) (HEV ORF1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call